KDR and neoplasm: Lenvatinib is an oral multi-kinase inhibitor that inhibits tumor cell proliferation and angiogenesis by targeting the VEGFR, fibroblast growth factor receptors (FGFR), PDGFR, rearranged during transfection (RET), and c-Kit.